The optimism surrounding psilocybin is not unfounded. Early clinical findings have been striking enough to attract serious scientific attention, substantial investment, and a level of public interest that neuropsychiatric drug development almost never generates. Treatment-resistant depression. End-of-life anxiety. Alcohol use disorder. These are conditions where existing treatments consistently fail patients, and the enthusiasm reflects that unmet need.
No more boards!